MTHFR and cancer: On the contrary, compounds like (S)-SKI-7218, which are potentially capable of fulfilling both SAM1 and SAM2 roles at the RD, could be developed as potent inhibitors, addressing disease states exhibiting MTHFR overexpression or hyperactivity that need to be down-regulated (e.g. cancer).